Rachel Legmann, PhD, Repligen, Waltham, MA, gives her perspectives on how to successfully develop viral vectors, including the need to have scalable process ready for commercialization. Dr Legmann additionally emphasizes the importance of the product meeting existing regulatory guidelines, especially before mass manufacturing, as well as choosing a suitable platform that can flexibly switch between different modalities, as the formulation will only need to be altered in such circumstances. This interview took place at Advanced Therapies Week 2022.
